All News

2020

October

Media Release / Oct 26, 2020

Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)

Read More
Media Release / Oct 23, 2020

Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)

Read More
Media Release / Oct 21, 2020

Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD)

Read More
Media Release / Oct 16, 2020

Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

Read More
Media Release / Oct 09, 2020

Novartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)

Read More
Collage of four portraits
Featured News / Oct 08, 2020

World Sight Day 2020

Learn how we’re working with partners like the International Agency for the Prevention of Blindness to eliminate preventable blindness.

Read More
Dr. Theophile Tuyisabe standing next to his patients smiling at him
Story / Oct 06, 2020

Meet a visionary who beat the odds to realize his vision of inclusive eye care

Dr. Theophile Tuyisabe is one of only 18 ophthalmologists in Rwanda. We spoke with him about how he does it.

Read More
Media Release / Oct 05, 2020

New Phase III analysis demonstrates Novartis Beovu® showed improvement in best-corrected visual acuity in wet AMD patients with early persistent fluid

Read More
Media Release / Oct 01, 2020

Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More